| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | blebbistatin | CTRPv2 | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.041 | 0.8 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | 0.009 | 0.8 |